Healthcare Equipment and Supplies
Company Overview of REVA Medical, Inc.
REVA Medical, Inc., a development stage medical device company, focuses on the commercialization of minimally invasive medical devices for the treatment of coronary artery disease in the human heart. It is developing and testing a bioresorbable stent to treat vascular disease in humans under the Fantom scaffolds name. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.
5751 Copley Drive
San Diego, CA 92111
Founded in 1998
Key Executives for REVA Medical, Inc.
Co-founder, Chairman and Chief Executive Officer
Total Annual Compensation: $430.5K
President and Chief Operating Officer
Total Annual Compensation: $447.1K
Chief Financial Officer and Company Secretary
Total Annual Compensation: $515.2K
Senior Vice President of Clinical and Regulatory Affairs
Total Annual Compensation: $353.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.7K
Compensation as of Fiscal Year 2014.
REVA Medical, Inc. Key Developments
Reva Medical, Inc. Expands FANTOM II Clinical Trial to Australia
May 15 15
REVA Medical, Inc. announced that the FANTOM II clinical trial is now enrolling patients with the Fantom sirolimus-eluting bioresorbable scaffold in Australia. This is in addition to previously announced sites in Brazil and Europe. The Fantom scaffold, made from REVA's advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial is enrolling patients to support a European CE Mark application, which is expected to occur by mid-2016.
REVA Medical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 14 15
REVA Medical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company's loss from operations of $4,853,000 compared to $7,272,000 a year ago. Net loss and comprehensive loss was $23,357,000 compared to $7,276,000 a year ago. Net loss per share, basic and diluted was $0.70 compared to $0.22 a year ago. Net cash used for operating activities was $4,962,000 compared to $6,649,000 a year ago. Purchases of property and equipment were $281,000 compared to $216,000 a year ago.
REVA Medical, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015
Apr 30 15
REVA Medical, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the period, the company's net operating cash outflows was $4,961,000. Payment for acquisition of physical non-current assets was $282,000.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|